Cargando…
Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Federation of Internal Medicine. Published by Elsevier B.V.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229910/ https://www.ncbi.nlm.nih.gov/pubmed/32425364 http://dx.doi.org/10.1016/j.ejim.2020.05.018 |
| _version_ | 1783534848381550592 |
|---|---|
| author | Levi, Marcel |
| author_facet | Levi, Marcel |
| author_sort | Levi, Marcel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7229910 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | European Federation of Internal Medicine. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72299102020-05-18 Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation Levi, Marcel Eur J Intern Med Commentary European Federation of Internal Medicine. Published by Elsevier B.V. 2020-06 2020-05-16 /pmc/articles/PMC7229910/ /pubmed/32425364 http://dx.doi.org/10.1016/j.ejim.2020.05.018 Text en © 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Commentary Levi, Marcel Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation |
| title | Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation |
| title_full | Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation |
| title_fullStr | Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation |
| title_full_unstemmed | Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation |
| title_short | Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation |
| title_sort | tocilizumab for severe covid-19: a promising intervention affecting inflammation and coagulation |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229910/ https://www.ncbi.nlm.nih.gov/pubmed/32425364 http://dx.doi.org/10.1016/j.ejim.2020.05.018 |
| work_keys_str_mv | AT levimarcel tocilizumabforseverecovid19apromisinginterventionaffectinginflammationandcoagulation |